排序方式: 共有3条查询结果,搜索用时 0 毫秒
1
1.
Karina Corona-Cervantes Alicia Parra-Carriedo Fernando Hernndez-Quiroz Noemí Martínez-Castro Juan Manuel Vlez-Ixta Diana Guajardo-Lpez Jaime García-Mena Csar Hernndez-Guerrero 《Nutrients》2022,14(5)
Obesity is a multifactorial disease resulting in excessive accumulation of fat. Worldwide, obesity is an important public health problem, affecting a large proportion of the world population. The tender cactus Opuntia ficus-indica, commonly known in Mexico as “nopal”, is widely distributed in this country, Latin America, South Africa, and the Mediterranean area. Nopal cladodes are commonly marketed in different forms as fresh, frozen, or pre-cooked, and used as fresh green vegetable. The aim of this study was to evaluate the capability of nopal to improve the health condition of participants affected by obesity, in a physical and dietary intervention, through gut microbiota modification. These results were contrasted with the effect of nopal in the gut microbiota of normal weight participants. We describe the association among biochemical, anthropometric markers, and the gut microbiota diversity found in fecal samples of the obese and normal weight groups. The results presented in this work suggest that caloric restriction, addition of nopal to the diet and physical activity, promote changes in the gut microbiota in obese women, improving the host metabolism, as suggested by the correlation between some bacterial species with biochemical and anthropometrical parameters. 相似文献
2.
Jaime Garc a-Mena Karina Corona-Cervantes Daniel Cuervo-Zanatta Tizziani Benitez-Guerrero Juan Manuel V lez-Ixta Norma Gabriela Zavala-Torres Loan Edel Villalobos-Flores Fernando Hern ndez-Quiroz Claudia Perez-Cruz Selvasankar Murugesan Fernando Guadalupe Bastida-Gonz lez Paola Berenice Z rate-Segura 《World journal of gastroenterology : WJG》2021,27(41):7065-7079
Coronavirus disease 2019 (COVID-19) is a disease produced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and it is currently causing a catastrophic pandemic affecting humans worldwide. This disease has been lethal for approximately 3.12 million people around the world since January 2020. Globally, among the most affected countries, Mexico ranks third in deaths after the United States of America and Brazil. Although the high number of deceased people might also be explained by social aspects and lifestyle customs in Mexico, there is a relationship between this high proportion of deaths and comorbidities such as high blood pressure (HBP), type 2 diabetes, obesity, and metabolic syndrome. The official epidemiological figures reported by the Mexican govern ment have indicated that 18.4% of the population suffers from HBP, close to 10.3% of adults suffer from type 2 diabetes, and approximately 36.1% of the population suffers from obesity. Disbalances in the gut microbiota (GM) have been associated with these diseases and with COVID-19 severity, presumably due to inflammatory dysfunction. Recent data about the association between GM dysbiosis and metabolic diseases could suggest that the high levels of susceptibility to SARS-CoV-2 infection and COVID-19 morbidity in the Mexican population are primarily due to the prevalence of type 2 diabetes, obesity, and metabolic syndrome. 相似文献
3.
Lucio Ventura-Ríos David Bañuelos-Ramírez María del Carmen Hernández-Quiroz Manuel Robles-San Román Fedra Irazoque-Palazuelos María Victoria Goycochea-Robles 《Reumatología clinica》2012,8(4):189-194
This work reports patient treatment survival and adverse events related to Biologic Therapy (BT), identified by a multicenter ambispective registry of 2047 rheumatic patients undergoing BT and including a control group of Rheumatoid Arthritis (RA) patients not using BT. The most common diagnoses were: RA 79.09%, Ankylosing Spondilytis 7.96%, Psoriatic Arthritis 4.40%, Systemic Lupus Erythematosus 3.37%, Juvenile Idiopathic Arthritis 1.17%. A secondary analysis included 1514 cases from the total sample and was performed calculating an incidence rate of any adverse events of 178 × 1000/ BT patients per year vs. 1009 x 1000/control group patients per year with a 1.6 RR (IC95% 1.4-1.9). For serious adverse events the RR was: 15.4 (95% CI 3.7-63.0, P<.0001). Global BT survival was 80% at 12 months, 61% at 24 months, 52% at 36 months and 45% at 48 months. SMR: 0.23 (95%CI 0.0-49.0) for BT vs. 0.00 (95%CI 0.0-0.2) for the control group. In conclusion, BT was associated to a higher infection risk and adverse events, compared to other patients. Mortality using BT was not higher than expected for general population with same gender and age. 相似文献
1